Compare TURB & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TURB | CMMB |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | Spain | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6M | 13.8M |
| IPO Year | 2023 | 2023 |
| Metric | TURB | CMMB |
|---|---|---|
| Price | $1.10 | $2.72 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 167.1K | 96.2K |
| Earning Date | 04-17-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $68.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.57 | $1.35 |
| 52 Week High | $20.44 | $3.55 |
| Indicator | TURB | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 32.48 | 84.02 |
| Support Level | $0.99 | $1.47 |
| Resistance Level | $1.11 | N/A |
| Average True Range (ATR) | 0.07 | 0.18 |
| MACD | -0.02 | 0.09 |
| Stochastic Oscillator | 10.08 | 87.19 |
Turbo Energy SA is an integrator of AI-driven energy storage and intelligent energy management solutions focused on transforming how energy is generated, stored, optimized, and consumed across residential, commercial, industrial, and utility-scale applications. It operates at the intersection of renewable energy infrastructure, energy storage, and software-driven optimization, combining battery systems, solar integration, and proprietary Artificial Intelligence (AI) technologies into unified intelligent energy platforms. Its solutions are designed to help customers reduce energy costs, improve operational resilience, increase energy independence, and optimize energy performance in increasingly decentralized and volatile energy markets. It generates the majority of its revenue from Spain.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.